Developing novel T cell therapeutics in cancer

TScan Therapeutics was co-founded by Longwood Fund in collaboration with Lasker Award-winner Stephen Elledge of Harvard Medical School. The novel platform allows for direct therapeutic development of anti-tumor TCRs by identification of their antigens in a genome-wide high-throughput manner, expanding the promise of immuno-oncology to patients not served by current cancer treatments. Christoph Westphal was the company’s Co-Founder and startup CEO and Longwood Principal Lea Hachigian was the company’s Co-Founder and startup President. TScan has closed two rounds of financing totaling $48 million from Longwood Fund, Google Ventures, Novartis Venture Fund, Bessemer Venture Partners, 6 Dimensions, and Novartis Institutes for BioMedical Research.

Visit Site

Related Press